25409167
OBJECTIVE	Rectal nonsteroidal anti-inflammatory drugs have been shown to reduce the incidence of postendoscopic retrograde cholangiopancreatography ( ERCP ) pancreatitis ( PEP ) .
OBJECTIVE	The aim of this study was to determine whether intramuscular diclofenac reduces the risk of PEP .
METHODS	Patients who underwent ERCP were randomized to receive either 90mg of diclofenac or placebo by intramuscular injection immediately after the procedure .
METHODS	PEP was defined as elevated serum amylase levels ( at least three times the upper limit of normal 24 hours after the procedure ) associated with new or worsened upper abdominal , epigastric , or back pain .
RESULTS	In total , 380 patients were randomized , and 343 were eligible for analysis .
RESULTS	The two groups were similar regarding clinical and demographic factors , as well as patient - and procedure-related risk factors for PEP .
RESULTS	PEP developed in 20/170 patients ( 11.8 % ) in the placebo group and in 22/173 patients ( 12.7 % ) in the diclofenac group ( P = 0.87 ) .
RESULTS	Multivariate regression analysis failed to illustrate that intramuscular diclofenac prevented PEP ( odds ratio 0.79 ; 95 % confidence interval 0.39-1 .25 ; P = 0.51 ) .
CONCLUSIONS	Prophylactic intramuscular diclofenac had no beneficial preventive effect on PEP.Clinicaltrials.gov NCT01717599 .

